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Epidemiological evidence suggests that genetic variants encoding enzymes involved in folate 
metabolism may modulate HNSCC risk by altering DNA methylation synthesis and genomic estability. 
Aim: A review of the literature on genetic polymorphisms involved in folate metabolism and risk 
of head and neck cancer was carried out.
Methodology: An electronic search was made on the Medline database to select papers on head 
and neck cancer and polymorphisms involved in folate metabolism.
Results: The association between MTHFR C677T polymorphism and the risk of this tumor type 
was evaluated in nine studies; there was an association with this disease in three papers. The MTR 
A2756G and MTRR A66G and RFC1 A80G polymorphisms were also associated with increased risk 
for HNSCC. MTHFD1 G1958A polymorphism was not associated with increased risk of this disease; 
the evaluation results of the MTHFR A1298C polymorphism in this neoplasm were contradictory. 
Other polymorphisms involved in folate metabolism were not studied for this neoplasm.
Conclusion: We conclude that polymorphisms involved in folate metabolism may modulate the risk 
of head and neck cancer, however, these results need to be demonstrated in different populations.
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INTRODUCTION
Head and neck carcinoma is the fifth most fre-
quent cancers; its incidence worldwide has been esti-
mated at 50,000 new cases each year1,2. The estimated 
rate for oral cancer in Brazil during 2010 was 14,120 
new cases (10,330 men and 3,790 women)3. Most of 
these epithelial tumors are classified as head and neck 
squamous cell carcinoma (HNSCC); the anatomical sites 
and occurrences in this group are the mouth (40%), the 
pharynx (15%), and the larynx (25%)2,4-6.
About two thirds of patients with these diseases 
present at advanced stages in which regional lymph 
nodes are generally involved. Distance metastases are 
present in 10% of patients7. The treatment varies depen-
ding on the stage of the disease; according to published 
data, about 60% to 65% of head and neck cancer patients 
may be cured by surgery and/or radiotherapy. Patients 
at initial stages of the disease (I and II) are treated by a 
single form of therapy (surgery or radiotherapy), while 
patients at more advanced stages (III and IV) require a 
combined approach, such as surgery and radiotherapy 
or chemotherapy8.
This cancer affects mostly males at more advanced 
age groups; the mean age at diagnosis is 60 years7,9. 
However, the incidence of cancer involving the base of 
tongue and the tonsils has increased in individuals aged 
below 45 years; this has been attributed to an increased 
prevalence of HPV infection, which is a contributing 
factor for this disease in developing countries10-11.
The main and well-established risk factors for 
this disease are smoking and alcohol abuse; these ha-
bits jointly multiply the risk of cancer, especially in the 
mouth and pharynx12. The reason for this is that ciga-
rettes contain about 4,700 substances, of which at least 
50 are carcinogenic. Frequent consumption of alcohol 
renders epithelial cells unable to form a protective barrier 
against external agents, thereby facilitating the action of 
cigarette carcinogens, which form DNA adducts that are 
not recognized in DNA replication processes13,14.
Hashibe et al.12 published a study showing that 
alcohol abuse, independently from smoking, elevated 
significantly the risk of oropharyngeal, hypopharynge-
al, and laryngeal cancer in individuals that had never 
smoked. Alcohol abuse may also cause nutritional de-
ficiencies because of altered intestinal absorption, and 
may alter important metabolic pathways, such as the 
folate metabolism, which is involved in cell methyla-
tion reactions. Consequently, gene methylation with a 
potential role in carcinogenesis may be compromised15.
Studies have suggested that poor oral hygiene is 
associated with a higher risk of head and neck cancer. 
Periodontal disease because of poor oral hygiene may 
result in infection; inflammation mediators – such as 
cytokines – are released and reactions against inflam-
mation occur, which may foster the development of 
cancer16. Loss of teeth may also facilitate the onset of 
mouth cancer, as the oral flora may become abnormal, 
and nitrite and nitrate reduction and production of 
acetaldehyde may occur, leading to formation of DNA 
adducts14,17.
Published papers have shows that a diet rich 
in whole cereals, fruit, and vegetables, and with few 
processed foods, together with a healthy life style, may 
confer protection against DNA oxidative damage. These 
foods contain micronutrients – vitamins B, C, E, carote-
noids, flavonoids, and other – that possess antioxidant 
and anticarcinogenic activity, which reduces the risk of 
oral cancer18-21.
Folate deficiency in the body – a vitamin that may 
be found in fruit and vegetables – has been associated 
with an increased risk of several types of cancer, inclu-
ding head and neck cancer20,22-26. This micronutrient is 
involved in DNA synthesis, repair, and methylation22,27.
OBJECTIVE AND METHODS
The purpose of this study was to carry out a 
review of the literature to present the results of studies 
that have assessed the modulation of polymorphisms 
involved in folate metabolism and the risk of head and 
neck cancer.
FOLATE METABOLISM
Folate is involved in forming methyl (CH3) groups 
during a carbon interconversion in the intermediate 
metabolism of S-adenosilmethionine (SAM), which is a 
methyl group donator in cell methylation reactions26,28,29. 
DNA methylation consists of transferring methyl groups 
to position 5 of cytosine residues that are located on 
cytosine-guanine dinucleotides (CpG); this occurs in 
reactions catalyzed by proteins named DNA methyltrans-
ferases30. This epigenetic DNA modification has several 
functional roles, such as controlling gene expression, 
stabilizing chromatin structure, and maintaining genomic 
stability23,26,29,30-34.
There are three mechanisms by which altered 
folate metabolism may contribute to carcinogenesis: (1) 
DNA hypomethylation and subsequent proto-oncogene 
activation26,35; (2) uracil misincorporation during DNA 
synthesis, leading to genomic instability26,35,36; and (3) 
increased cytosine deamination in DNA methylation 
sites26,36.
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Abnormal folate levels due to genetic polymor-
phisms in its metabolic pathway are associated with 
altered DNA methylation, synthesis and repair; adequate 
folate levels are essential for the biosynthesis of purines 
and pyrimidines, which are needed in these biological 
processes37-45.
Figure 1 shows the enzymes that are involved in 
folate metabolism. First, folate is converted or reduced 
into physiological folate by the dihydrofolate reductase 
(DHFR) enzyme. The serine hydroxymethyltransferase 
enzyme (SHMT) catalyzes a reversible reaction of THF 
into 5,10-MTHF; this enzyme is key in maintaining and 
regulating the homeostasis of folate concentration and 
intracellular methyl groups. It requires vitamin B
6
 and 
has a significant role in protein and DNA synthesis and 
in methylation reactions involving nucleic acids46,47.
nine is condensed with adenosine triphosphate (ATP), 
which results in S-adenosilmethionine (SAM). Next, in a 
demethylation reaction, S-adenosylhomocysteine (SAH) 
is formed and then hydrolyzed to release adenosine and 
Hcy, thereby completing the cycle48.
Hcy methylation replenished the stocks of SAM 
when methionine reaches lower levels. The betaine 
homocysteine methyltransferase (BHMT) enzyme ca-
talyzes the conversion of Hcy into methionine by an 
alternative remethylation pathway in which the betaine 
amino acid donates the methyl groups49-51. When the 
Hcy remethylation pathway – which is catalyzed by the 
folate-dependent MTR enzyme – is altered by genetic or 
environmental factors, the BHMT enzyme has a crucial 
role in Hcy homeostasis52.
Also involved is the cystathionine b-synthase 
(CbS) enzyme (also requiring vitamin B
6
), which has a 
crucial role in folate metabolism; it converts Hcy into 
cystathionine in the transsulfuration pathway53,54.
THF is recovered during the methionine regene-
ration cycle, after the methyl group (5-metil -THF) is 
donated to homocysteine. THF may be used directly 
– in another pathway – in the synthesis of thymidylate 
synthase (TS), which converts deoxyuridine mono-
phosphate (dUMP) into thymidine monophosphate 
(dTMP) by using the 10-formyl-THF for DNA synthesis. 
In this reaction, 5,10 methylene THF is the substrate of 
thymidylate55.
The methylenetetrahydrofolate dehydrogenase 1 
(MTHFD1) enzyme catalyzes the oxidation of 5,10-me-
thylene-THF into 5,10-methynyl-THF, which is then 
converted into 10-formyl-THF (Stevens et al., 2007). 
These three reactions are involved in the interconversion 
of THF carbon-1 derivates, which are the substrates for 
synthesizing methionine, thymidylate, and purines56.
Another enzyme is the reduced folate carrier 1 
(RFC1) enzyme, which is found on the membrane of 
intestinal mucosa cells, and which is involved in folate 
absorption. It does so by transporting 5-MTHF into se-
veral types of cells, and is an important determinant of 
folate concentration within cells48.
GENETIC POLYMORPHISMS INVOLVED IN 
FOLATE METABOLISM AND HEAD AND NECK 
CANCER
The MTHFR C677T polymorphism
This polymorphism is associated with decreased 
enzyme activity by limiting conversion of 5,10 methy-
lenetetrahydrofolate into 5-MTHFR, which is the folate 
form required for DNA methylation reactions57. A in vitro 
study has shown that the heterozygous 677CT genotype 
is associated with a 40% decrease in enzyme activity, 
Figure 1. Main enzymes involved in the folate metabolism. Folate 
metabolism – DHF: Dihydrofolate; THF- Tetrahydrofolate; DHFR: 
Dihydrofolate reductase; SHMT: Serine hydroxymethyltransferase; TYS: 
Thymidylate synthase; MTHFD1: Methylenetetrahydrofolate dehydro-
genesase 1; MTHFR: Methylene tetrahydrofolate reductase; MTR: 
methionine synthase; MTRR: Methionine synthase reductase; BHMT: 
Betaine-homocysteine methyltransferase; CBS: Cystathionine beta syn-
thase; RFC1: Reduced folate carrier 1; SAM: S S-adenosilmethyonine; 
SAH: S- adenosylhomocysteine; dUMP: Deoxyuridine monophosfate; 
dTMP: Thymidine monophosfate.
The methylenetetrahydrofolate reductase (MTHFR) 
enzyme catalyzes the conversion of 5,10 methylenete-
trahydrofolate into 5- methyltetrahydrofolate (5-MTHFR), 
which is the main circulating form of folate; it operates as 
a methyl group donor for the remethylation of homocys-
teine (Hcy) into methionine. This reaction is catalyzed by 
the methionine synthase enzyme (MTR), which requires 
vitamin B
12 
(methylcobalamin) as a cofactor, and which 
forms SAM. The methionine synthase reductase (MTRR) 
enzyme maintains the active state of the MTR enzyme. 
Following the methylation of Hcy, the resulting methio-
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while the polymorphic homozygote 677TT genotype 
is associated with a 70% decrease in enzyme activity58.
Additionally, the polymorphic homozygote geno-
type is associated with lower folate levels and higher 
homocysteine levels in blood plasma59-61; thus, reduced 
plasma folate levels may lead to hypomethylation of 
DNA and cancer62.
As far as we know, eight studies have assessed the 
association of this polymorphism with head and neck 
cancer37-44. Of these, only Reljic et al.’s41, Vairaktaris et 
al.’s40, and Solomon et al.’s43 papers have confirmed an 
association of the MTHFR C677T polymorphism with a 
risk of head and neck cancer (Chart 1).
Reljic et al41. conducted a case-control study of 
81 patients with head and neck cancer and 102 subjects 
without a history of cancer among a Croatian popula-
tion and found that the 677TT genotype decreases the 
risk of this disease. On the other hand, Vairaktaris et 
al.40 studied 110 subjects with mouth cancer and 102 
cancer-free individuals among Germans and Greeks and 
found that the 677CT genotype was associated with an 
increased risk of this cancer. Solomon et al.43 assessed 
126 individuals who were alcohol abusers (33 chronic 
and significant consumers of alcohol, 56 moderate 
consumers of alcohol, and 37 social drinkers) and who 
had mouth cancer and found that the 677TT genotype 
was associated with the group of chronic and significant 
alcohol abusers and the group of moderate consumers 
of alcohol (to a lesser degree).
The qMTHFR A1298C polymorphism
This variant has also been associated in vitro with 
decreased enzyme activity, although to a lesser degree 
compared to the MTHFR C677T polylmorphism63. A 
clear biological relevance of this polymorphism remains 
unclear and results so far are inconsistent62,64,65.
Data on the risk of head and neck cancer in rela-
tion to the MTHFR A1298C polymorphism is contradic-
tory. Suzuki et al.’s42 case-control study of 237 Japanese 
patients with head and neck cancer and 711 cancer-free 
individuals and Kruzsina et al.’s44 study of 131 Polish 
subjects with laryngeal cancer and 250 cancer-free Polish 
individuals found no association between this variant 
and the risk of head and neck carcinoma.
Neumann et al.’s39 study of 537 patients with 
head and neck cancer and 545 control subjects in Texas 
showed that individuals with the 1298AC or 1298CC ge-
notypes had a 35% lower risk of head and neck cancer. 
However, this study showed that the risk of HNSCC was 
higher in individuals with the three polymorphic alleles 
(MTHFR 677T, MTHFR 1298C, and MTHFR 1793A) com-
pared to subjects with one or two polymorphic alleles.
The MTR A2756G polymorphism
As far as we know, there are no in vitro studies 
that have assessed the activity of the MTR enzyme in the 
presence of the MTR A2756G polymorphism. Data on 
changes in Hcy and folate levels are contradictory66-71. A 
few authors have shown that individuals with the poly-
Chart 1. Studies on MTHFR C677T polymorphism in head and neck cancer.
Year Authors Study site Series
2002 Weistein et al. Caribbean
341 patients with cancer of the mouth and pharynx
521 control subjects
2004 Kureshi et al. Pakistan
50 patients with head and neck cancer
54 control subjects
2005 Neumann et al. Texas
537 patients with head and neck cancer
545 control subjects
2006 Reljic et al.* Croatia
81 patients with head and neck cancer
102 control subjects
2006 Vairaktaris et al.* Germany/Greece
110 patients com cancer of the mouth
120 control subjects
2007 Suzuki et al. Japan
237 patients with head and neck cancer
711 control subjects
2007 Hisuing et al. United States
278 patients with head and neck cancer
1.623 control subjects
2008 Solomon et al.* India
126 patients com cancer of the mouth
(33 chronic alcohol abusers, 56 moderate alcohol consumers, and 37 social alcohol drinkers)
2010 Kruzsina et al. Poland
131 patients com cancer of the larynx
250 control subjects
* Studies in which an association between polymorphism and the risk of head and neck cancer was found.
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morphic homozygote MTR 2756GG genotype present 
low Hcy and high folate levels68-71. On the other hand, 
Li et al.66 showed that Hcy levels are high if this variant 
is present, while Ma et al.67 showed that this polymor-
phism does not change Hcy levels.
Studies of DNA methylation have shown that the 
MTR 2756AG or GG genotypes decrease the formation 
of SAM, which results in DNA hypomethylation72. Other 
studies have also shown that there is a relation between 
the MTR 2756GG genotype and DNA hypomethylation 
in colorectal, breast, lung, and cervix cancers72-75.
Three studies have demonstrated the association 
between this polymorphism and head and neck cancer. 
Zhang et al.75 conducted a case-control study in Texas 
of 721 patients with head and neck cancer and 1,234 
individuals with no history of cancer and found that 
the MTR 2756AG or GG genotypes increased the risk 
of cancer. Kruzsina et al.’s44 study of 131 Polish subjects 
with laryngeal cancer and 250 controls also showed that 
these genotypes (MTR 2756GG or AG) were associated 
with this tumor type. Our group studied 236 Brazilian 
patients with head and neck cancer and 469 controls 
and found that the MTR 2756GG genotype and the MTR 
2756G allele were associated with an increased risk of 
HNSCC45. On the other hand, Suzuki et al.’s42 study of 
237 Japanese patients with head and neck cancer and 
711 controls revealed no association between this poly-
morphism and head and neck cancer.
The MTRR A66G polymorphism
Studies have shown that this variant generates 
an enzyme with low affinity for the MTR enzyme76. 
Gaughan et al.’s77 study showed that individuals with 
the MTRR 66GG genotype had low levels of Hcy in the 
blood plasma compared with individuals having the 
MTRR 66AA genotype. This effect, however, was not 
observed in other studies78,79.
Few studies have investigated an association of 
the MTRR A66G polymorphism and the risk of head and 
neck cancer. Suzuki et al.42 showed that this variant is 
not associated with a risk for head and neck cancer, but 
these authors also found an interaction between alcohol 
abuse and the MTRR A66G polymorphism in a Japanese 
population. Zhang et al.75 showed that individuals with 
the homozygous wild genotype (MTRR 66AA) are at a 
lower risk for head and neck cancer, confirming that 
the A allele is protective.
The RFC1 A80G polymorphism
The RFC1 gene is involved in intracellular fo-
late transport; it causes 5-MTHFR to be absorbed and 
transported into several cell types. The RFC1 A80G 
polymorphism may be involved in carcinogenesis by 
altering the concentration of plasmatic Hcy and folate, 
which in turn are associated with DNA methylation and 
repair. However, the exact biological mechanism of this 
polymorphism is not clear48,80-83.
Only our group evaluated the RFC1 A80G variant 
and its risk for head and neck cancer; we confirmed that 
the RFC1 80AG or 80AA genotypes were associated with 
an increased risk for these cancers, especially in males 
aged over 50 years that smoked cigarettes84.
Other polymorphisms of the folate metabolism
Only one study assessed the effect of the MTHFD1 
G1958A polymorphism in head and neck cancer; it 
found no associated risk for this disese44. Associations 
between head and neck cancer and the CBS 844ins68, 
BHMT G742A, SHMT C1420T, TC2 A67G, and TC2 
C776G polymorphisms, which are also involved in fo-
late metabolism, have not been studied; two of these 
polymorphisms have been associated with other types 
of cancer85-89.
CONCLUSION
The MTHFR C677T, MTHFR A1298C, MTR A2756G, 
MTRR A66G, and RFC1 A80G polymorphisms appear to 
modulate the risk of head and neck cancer. However, 
because of contradictory findings, studies of different 
populations are needed to clarify the role of these poly-
morphisms in the etiology of head and neck cancer.
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